According to the report, ablation devices are offering a minimal intrusive alternative to conventional surgical treatment of prostate, liver, lung cancers, and kidney, and it’s market segmentation is developing quickly due to the increase in the popularity of minimally intrusive treatments and the rise in the incidence of the soft tissue cancers.
For more information or any query mail at firstname.lastname@example.org
Key Players are:-
Abbott Laboratories, Boston Scientific, AngioDynamics, Johnson & Johnson, Medtronic, and other predominate & niche players.
Radiofrequency Ablation or RFA is a low intrusive procedure, appropriate for patients who are suffering from cardiac diseases (like atrial flutter, atrial fibrillation (AF), cardiac arrhythmias), and cancer and pain management. It is a method of choice due to its high efficacy, safety, and ease of use. There is an increase in the usage of RFA for the treatment of numerous diseases like cardiac arrhythmia and cancer. The ultrasound ablation technology’s use in RFAD is also improving the popularity of ablation devices. Yet, the market is restricted because of the low awareness about the procedure, high treatment cost, and availability of other treatments. As per the estimation, the impact of drivers is anticipated to be higher as compared to the limitations.
The Ablation product undertakes may increase the market during the forecast term. In April 2017, Medtronic launched the OsteoCool RF Ablation system as the indicator of bone metastases in Canada. It is the only RF ablation system who has dual-probe capabilities and can provide flexible, customized, and predictable treatment.
The research study covers the analysis of the global ablation devices market. It has been categorized based on three aspects such as product type, application, and regional. The market segmentation based on product includes capital, disposable, and reusable equipment. The sub-segmented disposable equipment considered as the largest market share in the year 2018 and as anticipated, it may witness the fastest CAGR during the forecast period. The segmentation of the Global Ablation Devices Market by application includes surgical oncology, pain management, cardiology, and cardiac rhythm management, cosmetology, and gynecology. The market based on the geographical aspect, the market classified into Asia-Pacific, Europe, North America, and LAMEA.
The Global Ablation Devices market segmentation based on regional aspect includes that as expected, North America will maintain its preeminence during the forecast period. Major factors that contribute to provincial growth are the high preponderance of cancer, high purchasing power, technological advancements, and government support for excellence healthcare. The Asia Pacific has anticipated exhibiting the fastest CAGR during the period of forecast. The advanced technology introduction includes a multi-needle electrode showcasing accuracy, cost-effectiveness, and portability is anticipated to have a favorable impact on the regional market of Ablation Devices. However, growing markets of India and China are also responsible to drive the market growth in the Asia Pacific region.
The Global Ablation Devices market is majorly growing by the increase in the prevalence of chronic and cardiovascular diseases and the importance of minimally intrusive surgeries. As per the Centers for Disease Control and Prevention (CDC), Atrial Fibrillation (AF) has been projecting to affect 17.9 million people in Europe by the end of 2060 and 12 million in the U.S. respectively by the end of 2050.
Table of Contents – Major Key Points
1 Industry Outlook
2 Report Outline
3 Market Snapshot
4 Market Outlook
5 Product Type: Market Size and Analysis
6 Technology: Percentage Split
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.
Company Name: Wiseguyreports.com
Contact Person: Norah Trent
Email: Send Email
Phone: +1 646 845 9349, +44 208 133 9349